A Study of Efficacy and Safety of PHP-201 in Patients With Primary Open Angle Glaucoma or Ocular Hypertension

Subject Inclusion Criteria: 1. The age of 19 years or older 2. Diagnosis of open-angle glaucoma (POAG) or ocular hypertension (OH) 3. Intraocular Pressure(IOP) ≤ 35mmHg at both eye and IOP ≥ 22mmHg at either eye 4. Shaffer's grading \> 2 5. Best-corrected visual acuity in both eye equivalent to 0.2logMar 6. Able and willing to give signed informed consent Subject Exclusion Criteria: 1. Central corneal thickness \<500㎛ or \>600㎛ 2. Medical history of following * Closed-angle glaucoma, pigment dispersion syndrome, pseudoexfoliation, narrow-angle glaucoma * Advanced glaucomatous loss; mean deviation (MD) \< -12dB * Moderate to severe inflammatory/infectious disease in either eye * Advanced retinopathy * Surgical or laser therapy for glaucoma treatment 3. Have confirmed the following at the screening visit * SBP ≥ 180mmHg or DBP ≥ 110mmHg * HbA1c \> 9.0% * CrCl \< 30mL/min * AST or ALT ≥ 3 X ULN * Unstable angina, myocardial infarction, transient ischemic attack, cerebral stroke, coronary artery bypass graft, or coronary angioplasty within 24 weeks * History of malignant tumor with 5 years * History of the causative disease that may cause secondary glaucoma, including a history of steroid administration for more than 4 weeks 4. Conditions need to wear contact lenses during the study 5. Known hypersensitivity to any component of the investigational product 6. Who has administered topical/systemic drugs that may affect the study within a certain period prior to eligibility check or are expected to need administration during the study duration * Prostaglandin analogues: 5 weeks * β-blockers: 4 weeks * ROCK inhibitors: 4 weeks * α/β-adrenergic agonists: 2 weeks * Muscarinic agonists: 1 week * Carbonic anhydrase inhibitors: 1 week * Systemic corticosteroids: 4 weeks 7. Pregnant or breast-feeding 8. Who disagreed with the use of the methods of proper contraception during the study duration 9. Administration or use of other investigational drugs/devices prior to the screening visit within its 5 half-lives or 30 days, whichever is longer 10. Unsuitable for participation in the study according to the judgment of the investigator